Protein / target
Tyrosine-protein kinase Lyn
Protein at a glance
Biological role
Non-membrane spanning protein tyrosine kinase activity
Primary system
Immune system
Strongest disease association
autoinflammatory disease, systemic, with vasculitis
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
2 approved · 7 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. Functions primarily as negative regulator, but can also function as activator, depending on the context. Required for the initiation of the B-cell response, but also for its down-regulation and termination. Plays an important role in the regulation of B-cell differentiation, proliferation, survival and apoptosis, and is important for immune self-tolerance. Acts downstream of several immune receptors, including the B-cell receptor, CD79A, CD79B, CD5, CD19, CD22, FCER1, FCGR2, FCGR1A, TLR2 and TLR4. Plays a role in the inflammatory response to bacterial lipopolysaccharide. Mediates the responses to cytokines and growth factors in hematopoietic progenitors, platelets, erythrocytes, and in mature myeloid cells, such as dendritic cells, neutrophils and eosinophils. Acts downstream of EPOR, KIT, MPL, the chemokine receptor CXCR4, as well as the receptors for IL3, IL5 and CSF2. Plays an important role in integrin signaling. Regulates cell proliferation, survival, differentiation, migration, adhesion, degranulation, and cytokine release. Involved in the regulation of endothelial activation, neutrophil adhesion and transendothelial migration (PubMed:36932076). Down-regulates signaling pathways by phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIM), that then serve as binding sites for phosphatases, such as PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1, that modulate signaling by dephosphorylation of kinases and their substrates. Phosphorylates LIME1 in response to CD22 activation. Phosphorylates BTK, CBL, CD5, CD19, CD72, CD79A, CD79B, CSF2RB, DOK1, HCLS1, LILRB3/PIR-B, MS4A2/FCER1B, SYK and TEC. Promotes phosphorylation of SIRPA, PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1. Mediates phosphorylation of the BCR-ABL fusion protein. Required for rapid phosphorylation of FER in response to FCER1 activation. Mediates KIT phosphorylation. Acts as an effector of EPOR (erythropoietin receptor) in controlling KIT expression and may play a role in erythroid differentiation during the switch between proliferation and maturation. Depending on the context, activates or inhibits several signaling cascades. Regulates phosphatidylinositol 3-kinase activity and AKT1 activation. Regulates activation of the MAP kinase signaling cascade, including activation of MAP2K1/MEK1, MAPK1/ERK2, MAPK3/ERK1, MAPK8/JNK1 and MAPK9/JNK2. Mediates activation of STAT5A and/or STAT5B. Phosphorylates LPXN on 'Tyr-72'. Kinase activity facilitates TLR4-TLR6 heterodimerization and signal initiation. Phosphorylates SCIMP on 'Tyr-107'; this enhances binding of SCIMP to TLR4, promoting the phosphorylation of TLR4, and a selective cytokine response to lipopolysaccharide in macrophages (By similarity). Phosphorylates CLNK (By similarity). Phosphorylates BCAR1/CAS and NEDD9/HEF1 (PubMed:9020138)
Subcellular location
Domains and Gene Ontology detail (121)Hide
Domains & features
Gene Ontology
- Cadherens junction
- Ccytoplasm
- Ccytoplasmic side of plasma membrane
- Ccytosol
- Cendocytic vesicle membrane
- Cextracellular exosome
- Cglutamatergic synapse
- CGolgi apparatus
- Cintegrin alpha2-beta1 complex
- Clysosomal membrane
- Cmembrane raft
- Cmitochondrial crista
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Haemostasis
- ·Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors…
- ·platelet-derived growth factor receptor binding
- ·platelet degranulation
- ·regulation of platelet aggregation
Kinase signalling
- ·Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors…
- ·kinase activity
- ·non-membrane spanning protein tyrosine kinase activity
- ·phosphorylation-dependent protein binding
Immune signalling
- ·Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors…
- ·adaptive immune response
- ·B cell homeostasis
- ·B cell proliferation
Synaptic signalling
- ·glutamatergic synapse
- ·postsynaptic specialization, intracellular component
Apoptosis & cell death
- ·positive regulation of dendritic cell apoptotic process
- ·regulation of B cell apoptotic process
Excitatory neurotransmission
- ·glutamatergic synapse
View underlying pathways (25)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Tyrosine-protein kinase Lyn inhibitor
Appears in clinical studies involving breast cancer, neoplasm, chronic myelogenous leukemia, BCR-ABL1 positive, chronic myelogenous leukemia, BCR-ABL1 positive
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 1,077 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 9 total
Obesity · type 2 diabetes mellitus · type 2 diabetes mellitus
chronic myelogenous leukemia, BCR-ABL1 positive · acute lymphoblastic leukemia · chronic myelogenous leukemia, BCR-ABL1 positive
juvenile myelomonocytic leukemia · acute myeloid leukemia · myelodysplastic syndrome
B-cell chronic lymphocytic leukemia · prostate cancer · leukemia
childhood leukemia · acute lymphoblastic leukemia · chronic myelogenous leukemia, BCR-ABL1 positive
colorectal carcinoma · breast carcinoma · exocrine pancreatic carcinoma
breast cancer · neoplasm · chronic myelogenous leukemia, BCR-ABL1 positive
macular degeneration · age-related macular degeneration
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Regulatory approval
Approval: BOSUTINIB (ANDA209624)
- Regulatory approval
Approval: BOSUTINIB (ANDA209543)
- New publicationEuropean LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
- Regulatory approval
Approval: Bosulif (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.